Lys219

Site Information
KIENGDRkLIGAQkK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 461340

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	liver cancer ( 4 , 5 ) , hepatocellular carcinoma ( 4 , 5 )
Relevant cell line - cell type - tissue:	HCT8/S11 (intestinal) ( 1 ) , HepG2 (hepatic) ( 4 , 5 ) , SW480 (intestinal) ( 2 ) , SW620 (intestinal) ( 3 )

References
1	Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
2	Li Y (2006) CST Curation Set: 1100; Year: 2006; Biosample/Treatment: cell line, SW480/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
3	Li Y (2006) CST Curation Set: 1103; Year: 2006; Biosample/Treatment: cell line, SW620/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
4	Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info